GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.